Health News Releases

  • Today May 1
Patient Safety Movement Foundation Outlines 2024 Action Plan for Creating a Safer Healthcare System
February 18, 2024 13:15
Patient Safety Movement Foundation Outlines 2024 Action Plan for Creating a Safer Healthcare System
At the Patient Safety Movement Foundation (https://psmf.org)’s annual Mid-Year Event on January 26, patient safety experts from around the world participated in the creation of an action plan to elimi
February 15, 2024 10:30
HistoSonics Awarded Key Position in UK’s Novel Innovation Program
HistoSonics®, (www.histosonics.com), the manufacturer of the Edison® System and novel histotripsy therapy platforms, announced today that the company’s Edison System has been selected to participate i
February 14, 2024 16:24
CORRECTING and REPLACING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU
Correction by Galderma: Results from the OLYMPIA program demonstrated that more than half of nemolizumab-treated patients achieved an at least four-point reduction in itch intensity, as measured by th
Newmont and Project C.U.R.E.’s partnership has created a positive economic ripple effect across 36 c
February 11, 2024 14:05
Newmont and Project C.U.R.E. - Two Decades of Partnership Delivering Global Medical Support
Newmont Corporation (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.newmont.com%2Fhome%2Fdefault.aspx&esheet=53893580&newsitemid=20240208935869&lan=en-US&anchor=Newmont+Corporat
February 11, 2024 11:15
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53894240&newsitemid=20240208344780&lan=en-US&anchor=TSE%3A4502%2FNYSE%
February 08, 2024 15:32
Galderma Takes the ‘Face of Cetaphil®’ to the Runway at New York Fashion Week
Cetaphil®, a leading dermatologist-recommended sensitive skincare brand, is launching a first-of-its-kind global skincare immersion. This immersion will put the sensitive skin science behind its formu
February 08, 2024 14:00
Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial
Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic biology, today announces the dosing of the first patient in their PARADIGM-1 Phase I/Ib
February 07, 2024 15:12
Galderma Launches ‘NEXT’, a Ground-Breaking Trend Report That Unveils the Future of Aesthetics
Galderma, the emerging pure-play dermatology category leader, is proud to present “NEXT by Galderma.” A ground-breaking report, NEXT takes a deep-dive into the global aesthetics trends set to shape 20
February 07, 2024 11:15
Parse Biosciences Partners with INTEGRA Biosciences for Automated Single Cell Workflows
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has entered into an agreement with INTEGRA Biosciences to integrate the Assist Plu
Professor Claude Wischik (Photo: Business Wire)
February 05, 2024 17:40
TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March
TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease (AD), announced today that the company will present the 24-month data from its Phase III LUCIDITY trial of hydr
February 05, 2024 14:40
Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders
Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting
February 04, 2024 13:24
Located in Seoul, Korea, Topcon Korea Medical Co., Ltd. (TKM) Was Established and Formally Launched in 2023.
Topcon Corporation (HQ: Itabashi-ku, Tokyo; President: Takashi Eto) (henceforth Topcon Healthcare) has established Topcon Korea Medical Co., Ltd. (HQ: Seoul, South Korea, President: Artur Chu) (hencef
February 04, 2024 11:26
Clinique Partners with Icahn School of Medicine at Mount Sinai to Establish the Mount Sinai-Clinique Healthy Skin Dermatology Center
Clinique and Icahn School of Medicine at Mount Sinai today announced a philanthropic partnership to establish the Mount Sinai-Clinique Healthy Skin Dermatology Center. The Center will develop forward-
February 04, 2024 11:00
Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-14323
We are excited to share our latest development status. As presented at 2022 ASCO Annual Meeting on June 6, 2022, DFP-14323 in combination with afatinib (20 mg/day) in stage III/IV non-small cell lu
February 04, 2024 10:51
Galderma Celebrates 25 Years of Excellence in Biostimulation With Sculptra® at the 2024 IMCAS
Galderma, the emerging pure-play dermatology category leader, is proud to celebrate 25 years of Sculptra®, which enjoys the trust of healthcare professionals and unmatched patient satisfaction. Sculpt
February 02, 2024 16:10
Takeda Announces Chief Financial Officer Succession
Takeda (TOKYO:4502/NYSE:TAK) today announced that Costa Saroukos, chief financial officer, has decided to leave Takeda to return to his home-country of Australia to be closer to family. Mr. Saroukos w
February 02, 2024 16:02
Galderma Celebrates 25 Years of Excellence in Biostimulation With Sculptra® at the 2024 IMCAS
Galderma, the emerging pure-play dermatology category leader, is proud to celebrate 25 years of Sculptra®, which enjoys the trust of healthcare professionals and unmatched patient satisfaction. Sculpt
February 02, 2024 14:40
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the third quarter of fiscal year 2023 (period ended December 31, 2023). With year-to-date strong momentum in its Growth & Launch Prod
(Photo: DEKA)
February 01, 2024 15:30
DEKA Plays Its Poker Quad With Four New Laser Platforms at IMCAS Paris, the World Dermatology and Plastic and Aesthetic Surgery Congress
DEKA, an Italian subsidiary of the El.En. Group, listed on the Eurostar Next of Borsa Italiana (ELN.MI), specialized in the development and production of pioneering Energy Based devices for aesthetics
Pico Filling Treatment - skin rejuvenation (Photo: Business Wire)
February 01, 2024 11:35
Quanta System unveils the latest breakthrough technology drawn on its picosecond laser heritage: VarioPulse Technology®, the next-level device for the next-level experts
Quanta System proudly opens the door to the New Year by unleashing the ultimate innovation in the picosecond laser technologies: Discovery PICO with VarioPulse Technology®. An unprecedented level of p
January 31, 2024 14:10
Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53888524&newsitemid=20240127162836&lan=en-US&anchor=%28TSE%3A4502%2FNY
Gilda D’Incerti, PQE Group CEO & Founder (Photo: Business Wire)
January 31, 2024 11:50
PQE Group: 100+M€ in Revenues
PQE Group (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww2.pqegroup.com%2F&esheet=53889015&newsitemid=20240129526587&lan=en-US&anchor=PQE+Group&index=1&md5=5321f09b4f01e443d0714
January 30, 2024 14:06
Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53887989&newsitemid=20240125010746&lan=en-US&anchor=TSE%3A4502%2FNYSE%
January 28, 2024 10:30
New Independent Clinical Study Showcases Safety and Efficacy of GC Aesthetics’ PERLE Breast Implant
GC Aesthetics® (GCA), a privately-held medical technology company providing aesthetic and reconstruction solutions for global healthcare markets, is proud to announce that its breast implant, PERLE™,
January 26, 2024 13:30
Kenvue Declares Quarterly Cash Dividend
Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the first quarter
25 per page50 per page75 per page100 per page